Abbott Will Study Prostate Cancer Drug Atrasentan For Early-Stage/Prevention
Executive Summary
Abbott plans to file an NDA for its prostate cancer therapy atrasentan in late 2003, the company told securities analysts at its June 21 R&D Day in New York City.
You may also be interested in...
Abbott atrasentan filing delay
Abbott will not file NDA for oncologic agent atrasentan (ABT-627) until 2004, following the failure of drug to reach its primary endpoint of time-to-progression in a Phase III trial evaluating patients with advanced metastatic hormone-refractory prostate cancer. Abbott previously hoped to file in late 2003 (1"The Pink Sheet" July 2, 2001, p. 22)...
Abbott atrasentan filing delay
Abbott will not file NDA for oncologic agent atrasentan (ABT-627) until 2004, following the failure of drug to reach its primary endpoint of time-to-progression in a Phase III trial evaluating patients with advanced metastatic hormone-refractory prostate cancer. Abbott previously hoped to file in late 2003 (1"The Pink Sheet" July 2, 2001, p. 22)...
Abbott Compound Library Near 1 Mil., Company Tells Analysts At R&D Day
Abbott's compound library is nearing 1 mil. molecules, the company told securities analysts during its June 21 R&D day in New York.